SUJAY KUMAR SINGH
Pilots at Corte Famosa, San Diego, CA
License number
California A3556125
Issued Date
Mar 2015
Expiration Date
Mar 2017
Category
Airmen
Type
Authorized Aircraft Instructor
Address
Address
4294 Corte Famosa, San Diego, CA 92130
Professional information
Compositions And Methods For Improved Detection And Classification Of Neoplasms
US Patent:
6623936, Sep 23, 2003
Filed:
Feb 7, 2000
Appl. No.:
09/499559
Inventors:
Peter Dias - San Diego CA
Sujay Singh - San Diego CA
Sujay Singh - San Diego CA
Assignee:
Imgenex - San Diego CA
International Classification:
G01N 3353
US Classification:
435 72, 435 6, 435 71, 435 79, 435 791, 435 793, 435 795, 530350, 5303871
Abstract:
A method for diagnosing clinically distinct embryonal and alveolar subtypes of rhabdomyosarcoma, including contacting a reagent including an antibody that specifically binds myogenin with a sample that includes at least one rhabdomyosarcoma cell or at least one extract of at least one rhabdomyosarcoma cell, detecting the binding of the antibody to the sample to determine the presence, absence, or amount of myogenin in the sample, and diagnosing clinically distinct embryonal and alveolar subtypes of rhabdomyosarcoma, alveolar rhabdomyosarcoma having an increased amount of binding as compared to embryonal rhabdomyosarcoma.
Transgenic Avian Species For Making Human And Chimeric Antibodies
US Patent:
2004025, Dec 9, 2004
Filed:
Dec 9, 2003
Appl. No.:
10/731073
Inventors:
Sujay Singh - San Diego CA, US
Peter Dias - Carlsbad CA, US
Peter Dias - Carlsbad CA, US
International Classification:
A01K067/027
US Classification:
800/019000, 119/300000
Abstract:
The present invention provides methods for producing exogenous and chimeric antibodies in avians. One aspect of the present invention is a method of producing avians or avian cells lacking endogenous immunoglobulin light chain and heavy chain loci, or portions thereof, and having at least a portion of at least one exogenous immunoglobulin locus. The present invention provides a method for obtaining an avian cell with a deletion in an endogenous immunoglobulin locus by by introducing a targeting construct comprising two regions of sequences which are homologous to the 5′ and 3′ flanking sequences of the region to be deleted in the wild-type locus. In addition, the invention provides methods for inserting exogenous immunoglobulin gene loci into the genome of an avian cell. A second aspect of the invention is the generation of transgenic avian species or transgenic avian cells for producing chimeric antibodies. The avian host is characterized by: (1) being incapable of producing endogenous immunoglobulin; and (2) having at least a portion of an exogenous immunoglobulin locus comprising at least one immunoglobulin constant region or portion thereof. Specific binding proteins with xenogenic regions can be produced in a viable avian host by immunization of the avian host with an appropriate immunogen. Another aspect of the invention is the isolation of antibody-producing cells from a transgenic avian of the present invention that has been immunized with an antigen of interest. The cells can be immortalized for the production of antibody in culture. The immortalized cells can be used for the isolation of cDNAs encoding immunoglobulin heavy and light chains or portions thereof. The cDNAs can be reintroduced to cell lines, including mammalian cell lines for efficient production of monoclonal antibodies. The cDNAs can optionally be mutated or altered, for example, such that they encode higher avidity antibodies or chimeric immunoglobulin molecules, prior to reintroduction into cell lines.
Transgenic Avian Species For Making Human And Chimeric Antibodies
US Patent:
2002002, Mar 7, 2002
Filed:
Jun 18, 2001
Appl. No.:
09/884579
Inventors:
Sujay Singh - San Diego CA, US
Peter Dias - Carlsbad CA, US
Peter Dias - Carlsbad CA, US
International Classification:
A01K067/027, C12P021/04, C07K016/00
US Classification:
435/070210, 800/019000, 530/388100
Abstract:
The present invention provides methods for producing exogenous and chimeric antibodies in avians. One aspect of the present invention is a method of producing avians or avian cells lacking endogenous immunoglobulin light chain and heavy chain loci, or portions thereof, and having at least a portion of at least one exogenous immunoglobulin locus. The present invention provides a method for obtaining an avian cell with a deletion in an endogenous immunoglobulin locus by by introducing a targeting construct comprising two regions of sequences which are homologous to the 5′ and 3′ flanking sequences of the region to be deleted in the wild-type locus. In addition, the invention provides methods for inserting exogenous immunoglobulin gene loci into the genome of an avian cell. A second aspect of the invention is the generation of transgenic avian species or transgenic avian cells for producing chimeric antibodies. The avian host is characterized by: (1) being incapable of producing endogenous immunoglobulin; and (2) having at least a portion of an exogenous immunoglobulin locus comprising at least one immunoglobulin constant region or portion thereof. Specific binding proteins with xenogenic regions can be produced in a viable avian host by immunization of the avian host with an appropriate immunogen. Another aspect of the invention is the isolation of antibody-producing cells from a transgenic avian of the present invention that has been immunized with an antigen of interest. The cells can be immortalized for the production of antibody in culture. The immortalized cells can be used for the isolation of cDNAs encoding immunoglobulin heavy and light chains or portions thereof. The cDNAs can be reintroduced to cell lines, including mammalian cell lines for efficient production of monoclonal antibodies. The cDNAs can optionally be mutated or altered, for example, such that they encode higher avidity antibodies or chimeric immunoglobulin molecules, prior to reintroduction into cell lines.
Selective Inhibitors Of Nuclear Factor Kappab Activation And Uses Thereof
US Patent:
2009011, Apr 30, 2009
Filed:
Mar 25, 2008
Appl. No.:
12/055164
Inventors:
Bharat B. Aggarwal - Houston TX, US
Sujay Singh - San Diego CA, US
Sujay Singh - San Diego CA, US
International Classification:
A61K 38/10
US Classification:
514 14
Abstract:
The present invention provides cell permeable NF-κB inhibitors consist of a polypeptide derived from the p65 subunit of NF-κB and a protein transduction domain derived from antennapedia third helix sequence. The inhibitor suppressed NF-κB activation induced by TNF, LPS, IL-1, okadaic acid, PMA, HOand cigarette smoke condensate. NF-κB-regulated reporter gene expression induced by TNF, TNFR1, TRADD, TRAF2, NIK, IKK and p65 was suppressed by the inhibitor. The inhibitor enhanced TNF- and chemotherapeutic agent-induced apoptosis. Overall these results demonstrate a NF-κB inhibitor that can selectively inhibit NF-κB activation induced by various inflammatory stimuli, down-regulate NF-κB mediated gene expression and upregulate apoptosis.
Inhibitors Of Receptor Activator Of Nf-Κb And Uses Thereof
US Patent:
6998383, Feb 14, 2006
Filed:
May 10, 2002
Appl. No.:
10/143293
Inventors:
Bharat Aggarwal - Houston TX, US
Bryant G. Darnay - Houston TX, US
Sujay Singh - San Diego CA, US
Bryant G. Darnay - Houston TX, US
Sujay Singh - San Diego CA, US
Assignee:
Research Development Corporation - Carson City NV
International Classification:
A61K 38/18, C07K 14/475, C07K 19/00, C12N 5/02
US Classification:
514 2, 435375, 514 12, 530300, 530324, 530350
Abstract:
The present invention provides a RANK (receptor activator of NF-κB) inhibitor consisted of a TRAF-6 (TNF receptor-associated factor-6) binding domain attached to a leader sequence. The peptide inhibitor inhibits RANKL (RANK ligand)-mediated osteoclast differentiation, thus indicating that targeted disruption of interaction between RANK and TRAF6 may prove useful as a therapeutic for metabolic bone disorders, leukemia, arthritis, and metastatic cancer of the bone.
Selective Inhibitors Of Nuclear Factor-Κb Activation And Uses Thereof
US Patent:
7368430, May 6, 2008
Filed:
Nov 4, 2004
Appl. No.:
10/981082
Inventors:
Bharat B. Aggarwal - Houston TX, US
Sujay Singh - San Diego CA, US
Sujay Singh - San Diego CA, US
Assignee:
Research Development Foundation - Carson City NV
International Classification:
A61K 38/00
US Classification:
514 14
Abstract:
The present invention provides cell permeable NF-κB inhibitors consist of a polypeptide derived from the p65 subunit of NF-κB and a protein transduction domain derived from antennapedia third helix sequence. The inhibitor suppressed NF-κB activation induced by TNF, LPS, IL-1, okadaic acid, PMA, HOand cigarette smoke condensate. NF-κB-regulated reporter gene expression induced by TNF, TNFR1, TRADD, TRAF2, NIK, IKK and p65 was suppressed by the inhibitor. The inhibitor enhanced TNF- and chemotherapeutic agent-induced apoptosis. Overall these results demonstrate a NF-κB inhibitor that can selectively inhibit NF-κB activation induced by various inflammatory stimuli, downregulate NF-κB mediated gene expression and upregulate apoptosis.
Transgenic Animals For Use In Protein Expression And Antibody Production
US Patent:
2004009, May 20, 2004
Filed:
Oct 29, 2003
Appl. No.:
10/696162
Inventors:
Sujay Singh - San Diego CA, US
International Classification:
A01K067/027, C12N015/86
US Classification:
800/014000, 800/015000, 800/016000, 800/017000, 800/018000, 800/019000, 800/020000, 435/456000
Abstract:
The present invention concerns transgenic vertebrates that are useful in expressing proteins and in producing antibodies. The present invention discloses methods for producing vertebrates that are transgenic for a bacteriophage RNA polymerase. The present invention further discloses methods for the use of such transgenic vertebrates in protein expression and in antibody production.
Inhibitors Of Receptor Activator Of Nf-Kappab And Uses Thereof
US Patent:
2004016, Aug 26, 2004
Filed:
Feb 25, 2004
Appl. No.:
10/786316
Inventors:
Bharat Aggarwal - Houston TX, US
Bryant Darnay - Houston TX, US
Sujay Singh - San Diego CA, US
Bryant Darnay - Houston TX, US
Sujay Singh - San Diego CA, US
International Classification:
A61K038/16, C07K014/16
US Classification:
514/012000, 530/350000
Abstract:
The present invention provides a RANK (receptor activator of NF- B) inhibitor consisted of a TRAF-6 (TNF receptor-associated factor-6) binding domain attached to a leader sequence. The decoy peptide inhibits RANKL (RANK ligand)-mediated osteoclast differentiation, thus indicating that targeted disruption of interaction between RANK and TRAF6 may prove useful as a therapeutic for metabolic bone disorders, leukemia, arthritis, and metastatic cancer of the bone.